ABSTRACT
INTRODUCTION
The biopsy of the urinary bladder is a minimally invasive procedure, which is commonly employed for detection of urinary bladder pathology (such as carcinoma in situ, interstitial cystitis, etc).
Several studies suggest that the analgesia, which can be obtained with intravesical instillation before transurethral biopsy of the urinary bladder, may offer an acceptable level of analgesia, although this procedure does not totally eliminate patient's complaints by using this method (1-5).
Clinical Urology
The aim of this pre-emptive study was to attempt to estimate the analgesic effect during the biopsy procedure, which may be administered by either the simple instillation of ropivacaine or the combined instillation and subepithelial injection of the same agent. A comparison between the two methods was accordingly performed.
MATERIALS AND METHODS
Fifty-two randomized patients (30 male, 22 female) with an age range 25-86 (mean 56.42) were enrolled in this study. All patients were fully informed regarding both the procedure and the type of analgesia and provided their written consent, which was formulated according to local legislation.
The patients were randomized so that 50% of them (16M, 10F) received simple intravesical instillation of ropivacaine (Group A) whereas the other 26 patients (14M, 12F) received both intravesical instillation and sub epithelial injection at the site of biopsy (Group B). Cup biopsies were performed for histopathologic examination of suspicious for nonexophytic neoplasia areas of bladder urothelium, mainly carcinoma in situ (CIS).
In each patient intraurethral lubrication with lidocaine hydrochloride 2% gel was performed before the procedure. Then, a 10F Nelaton catheter was used for intravesical instillation of 100 mL solution of ropivacaine (2 mg/mL), 30 minutes before the biopsy.
In the endoscopic operation room of our department a diagnostic cystoscopy was performed using a 24F rigid endoscope (Karl Storz). In the Group A, biopsies were obtained in a straightforward manner using grasp forceps. In the Group B a flexible metal needle (Karl Storz 27184A) was inserted through the working channel of the rigid endoscope. After the detection of the suspicious area, submucosa injection 2 mL of ropivacaine 2 mgr/mL was performed taking care to avoid bleeding of the area, which subsequently was biopsied with grasp forceps (cup biopsy). In both groups biopsies were from 3 to 4.
Each patient was asked to estimate the severity of pain during the procedure using the Visual Analogue Scale (VAS) from 0 to 10 and remained in the Urology Department for a short-term observation.
The VAS values and the gender of each patient were recorded. Statistically significant differences (p < 0.05) between the VAS values between the two Groups were analyzed based on the type of analgesia and the gender, using the Student's-t-test for independent samples (two tailed).
RESULTS
The entire procedure was integrated with success in 50 out of 52 patients. In 2 patients the procedure was not completely performed due to poor endoscopic conditions (low visibility caused by prostate bleeding in the presence of enlarged prostate). One of these patients was in Group A and one in Group B.
The VAS score for the Group A ranged from 4 to 6 (mean 5.08), whereas for the Group B from 1 to 3 (mean 1.6) (p < 0.0001). In each group (A and B), the VAS values were significantly higher in men than in women of the same Group (p = 0.0005 and p < 0.0001, respectively) ( Table-1 ). Statistically significant difference (p < 0.0001) was observed in VAS values depending on gender between the two groups ( Table-1) .
There was no systemic adverse effect from ropivacaine. Due to complications of this method, a slight bleeding (hematuria) occurred in 6 of 50 patients (2 from Group B and 4 from Group A), which was resolved using oral administration of water. Allergic reactions were not recorded. Hospitalization never exceeded 3 hours after the procedure.
COMMENTS
Minimally invasive techniques are employed in routine urological surgery with increasing frequency, possibly due to the demand for treating patients by one-day surgery. The employment of local anesthesia offers a large variety of benefits such as the patient's safety (2,5,6), minimal hospitalization, the reduction of any complications associated with general or epidural anesthesia and the low cost (4,6,7).
Although pain is a subjective symptom, the employment of the VAS score was used for the purpose of this study in order to estimate, as objectively as possible, this reaction in our patients (from slight discomfort to severe pain).
The intravesical instillation of a local anesthetic was initially described in 1991 (1,2) and since then many authors have followed the same practice, as referred in many studies. Although the administration of lidocaine by EMDA technique offers effective anesthesia at the level of urothelium (8,9), it is a rather sophisticated method. Intravesical instillation is safe, since the levels of Lidocaine are significantly much lower as regards the toxic levels, even if the technique is employed on denuded urothelium and almost totally harmless whenever the technique is employed on intact urothelium (1-3,5,10). In addition to lidocaine, other local anesthetics such as bupivacaine have been employed either intravesically or as subtrigonal injection (6,11,12) without any adverse effects.
Ropivacaine is the pure S (-) enantiomer of N-propyl-2'6-pipecoloxylidide and created from the need to produce a local anesthetic effective over a long period without any cardio toxicity which is, although very rarely the case , associated with bupivacaine. Ropivacaine prohibits both the initiation and the transmission of neural signals by reduction of membrane permeability of the neural cell in Na+. The consequential arrest of depolarization leads to conductibility arrest. Small neural fibers are more sensitive to this effect and therefore demand a longer period of rehabilitation. The sensory fibers of pain are the first that are usually blocked. The extension of anesthesia depends on the diffusion of the solution, which is mostly affected by the area where this solution is administered and by the amount of the administered solution (13). To our knowledge, it is the first time that ropivacaine was employed for both local intravesical and submucosa anesthesia of the bladder. The concentration of 2 mg/mL was empirically selected in this study.
In addition, although the employment of the submucosa injection of a local anesthetic has proved efficacious for transurethral resection of superficial bladder tumors (6) and the intravesical instillation of similar agents have been used for minimal transurethral operations (14-16), this is the first time that a combination of both techniques was performed.
As clearly demonstrated in our study by the difference in VAS values between the two groups, the injection of ropivacaine by needle at the biopsy site combined with the intravesical instillation of the same agent offers greater reduction of pain than simple instillation of the same agent. Therefore, it is clearly suggested that the submucosa injection improves the analgesic effect of a local anesthetic, which was previously instilled into the urinary bladder. The superiority of the combined technique (intravesical instillation plus submucosa injection) as compared to simple instillation may be attributed to the prohibition of signals from sensory receptors to the centripetal C fibers, which form a submucosa network at the bladder wall. This network is responsible for activation of detrusor muscle. The action of local anesthetics, as has been proved recently, is not limited only to sensory fibers but extends to the centrifugal neural fibers and to the detrusor muscle, although this extended action demands higher concentrations (17). Male patients experienced more pain than women possibly due to the differences in the anatomy of the lower urinary tract between two sexes, such as already mentioned by others (18).
Our method is easily applicable and safe. All cases were performed on an outpatient basis. The slight hematuria in a small number of patients subsided soon after the procedure and was mostly attributed to the effect of tissue resection from biopsy and not to the puncture of bladder wall for injecting the local anesthetic.
Furthermore, our results suggest that the analgesic effect of the combination of both submucosa injection and intravesical instillation (mean VAS value 1.6 in a 10-scale VAS) might be similar to the analgesic effect of caudal anesthesia during transurethral biopsies of urinary bladder with forceps (mean VAS value 0.8 in a 5-scale VAS) (5). Therefore, if our observation is confirmed in a larger number of patients, any type of anesthesia could be replaced by this method, whenever there is a need for bladder biopsies or, at least, in patients who are at high risk for other types of anesthesia.
CONCLUSIONS
Transurethral biopsies of the urinary bladder can be performed with high level of analgesia whenever the combination of intravesical instillation and submucosa injection of ropivacaine is employed. The analgesic effect of this combination could be similar to caudal anesthesia and significantly superior as compared to simple instillation. Therefore, the intravesical instillation and the simultaneous submucosa injection of ropivacaine can safely replace caudal or general anesthesia and their subsequent morbidity when there is need for urinary bladder biopsies or any other minimal invasive transurethral procedure of the urinary bladder.
